Nykode Therapeutics AS
5VB
Company Profile
Business description
Nykode Therapeutics AS is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company is developing individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate therapeutics to treat cancers with a high unmet medical need using it's modular immunotherapy technology, specifically targeting antigens to Antigen Presenting Cells, which are essential for inducing rapid and long-lasting immune responses. It operates in United States of America.
Contact
Gaustadalleen 21
Oslo Research Park
Oslo0349
NORT: +47 22958193
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
59
Stocks News & Analysis
stocks
Two cheap wide moat ASX shares
These shares are trading at a discount to our fair value discount and have sustainable competitive advantages.
stocks
Anthropic: Are the shares undervalued given the IPO pricing range?
There may be meaningful upside as Anthropic is pricing its stock as a reflection of current sentiment, not the company’s fundamentals.
stocks
Valuation looks stretched for ASX healthcare share
Strong fundamentals meet a demanding valuation.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,291.30 | 23.50 | 0.25% |
| CAC 40 | 8,332.87 | 54.28 | 0.66% |
| DAX 40 | 26,662.77 | 315.32 | 1.20% |
| Dow JONES (US) | 52,486.49 | 254.60 | 0.49% |
| FTSE 100 | 10,835.47 | 83.88 | 0.78% |
| HKSE | 24,315.92 | 241.12 | -0.98% |
| NASDAQ | 25,466.19 | 400.32 | 1.60% |
| Nikkei 225 | 61,248.59 | 789.01 | 1.31% |
| NZX 50 Index | 14,215.29 | 35.43 | 0.25% |
| S&P 500 | 7,619.38 | 98.45 | 1.31% |
| S&P/ASX 200 | 9,153.20 | 24.20 | 0.27% |
| SSE Composite Index | 3,680.64 | 16.92 | 0.46% |